Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUFIRI-bevacizumab versus FOLFIRI-bevacizumab in previously treated unresectable metastatic colorectal cancer
2022-001459-17Phase 2Completed
- Sponsor
- NuCana
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fosifloxuridine nafalbenamide in colorectal adenocarcinoma (2 arms), sponsored by NuCana. Primary endpoint: Progression-free survival. Started Nov 2022; status: completed.
02
Drugs
fosifloxuridine nafalbenamide
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2022-001459-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001459-17.